Cargando…

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia

X‐linked hypophosphatemia (XLH) is a rare genetic disorder that disrupts skeletal and dental mineralization. In addition to rickets in children, XLH patients also have frequent spontaneous dental abscesses that increase the risk of tooth loss and may lead to facial cellulitis. Hypomineralized and hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gadion, Margaux, Hervé, Agathe, Herrou, Julia, Rothenbuhler, Anya, Smail‐Faugeron, Violaine, Courson, Frédéric, Linglart, Agnès, Chaussain, Catherine, Biosse Duplan, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664523/ https://www.ncbi.nlm.nih.gov/pubmed/36398111 http://dx.doi.org/10.1002/jbm4.10672

Ejemplares similares

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone
por: Ertl, Diana-Alexandra, et al.
Publicado: (2022)

Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration
por: Nguyen, Caroline, et al.
Publicado: (2021)

Growth hormone treatment improves final height in children with X-linked hypophosphatemia
por: André, Julia, et al.
Publicado: (2022)

Therapeutic management of hypophosphatemic rickets from infancy to adulthood
por: Linglart, Agnès, et al.
Publicado: (2014)

Dental erosion in French adolescents
por: Muller-Bolla, Michèle, et al.
Publicado: (2015)

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
por: Mughal, M. Zulf, et al.
Publicado: (2023)

Methodological quality and implications for practice of systematic Cochrane reviews in pediatric oral health: a critical assessment
por: Smaïl-Faugeron, Violaine, et al.
Publicado: (2014)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

SUN-336 Obesity and Impaired Glucose Metabolism in Adult Patients with X-Linked Hypophosphatemia
por: Lecoq, Anne-Lise, et al.
Publicado: (2020)

Comparison of intervention effects in split-mouth and parallel-arm randomized controlled trials: a meta-epidemiological study
por: Smaïl-Faugeron, Violaine, et al.
Publicado: (2014)

Erratum to: “Comparison of intervention effects in split-mouth and parallel-arm randomized controlled trials: a meta-epidemiological study”
por: Smaïl-Faugeron, Violaine, et al.
Publicado: (2015)

Prevalence and risk indicators of first-wave COVID-19 among oral health-care workers: A French epidemiological survey
por: Jungo, Sébastien, et al.
Publicado: (2021)

Split-mouth and parallel-arm trials to compare pain with intraosseous anaesthesia delivered by the computerised Quicksleeper system and conventional infiltration anaesthesia in paediatric oral healthcare: protocol for a randomised controlled trial
por: Smaïl-Faugeron, Violaine, et al.
Publicado: (2015)

Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia
por: Zhukouskaya, Volha V, et al.
Publicado: (2020)

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives
por: Seefried, Lothar, et al.
Publicado: (2023)

Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
por: Martín Ramos, Silvia, et al.
Publicado: (2020)

Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
por: Khadora, Manal, et al.
Publicado: (2021)

A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature
por: Rothenbuhler, Anya, et al.
Publicado: (2015)

Erratum to: A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature
por: Rothenbuhler, Anya, et al.
Publicado: (2017)

SAT-259 Natural History of Anthropometric Parametres of Obesity in Children Affected by X-Linked Hypophosphatemia: Longitudinal Obserbational Study
por: Zhukouskaya, Volha, et al.
Publicado: (2019)

Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review
por: Jurca, Claudia Maria, et al.
Publicado: (2022)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

Development of a Core Set of Outcomes for Randomized Controlled Trials with Multiple Outcomes – Example of Pulp Treatments of Primary Teeth for Extensive Decay in Children
por: Smaïl-Faugeron, Violaine, et al.
Publicado: (2013)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Impact of Early Conventional Treatment on Adult Bone and Joints in a Murine Model of X-Linked Hypophosphatemia
por: Cauliez, Axelle, et al.
Publicado: (2021)

Dramatic Transformation After Burosumab in a Young Boy With X-linked Hypophosphatemia: A Life-Changing Saga
por: Baradhi, Krishna
Publicado: (2022)

A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome
por: Merz, Lea Maria, et al.
Publicado: (2022)

Development of Enthesopathies and Joint Structural Damage in a Murine Model of X-Linked Hypophosphatemia
por: Faraji-Bellée, Carole-Anne, et al.
Publicado: (2020)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
por: Namba, Noriyuki, et al.
Publicado: (2022)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

MEPE-Derived ASARM Peptide Inhibits Odontogenic Differentiation of Dental Pulp Stem Cells and Impairs Mineralization in Tooth Models of X-Linked Hypophosphatemia
por: Salmon, Benjamin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sslg3jfl787bn28i55009h8ih3